Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

Arthritis Rheum. 2011 Apr;63(4):867-70. doi: 10.1002/art.30207.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adalimumab
  • Antibodies, Anti-Idiotypic / blood
  • Antibodies, Anti-Idiotypic / genetics
  • Antibodies, Anti-Idiotypic / immunology*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / immunology
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Drug Therapy, Combination
  • Humans
  • Immunogenetic Phenomena / genetics
  • Immunogenetic Phenomena / immunology
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy / adverse effects*
  • Incidence
  • Methotrexate / therapeutic use
  • Risk Factors
  • Thromboembolism / epidemiology*
  • Thromboembolism / immunology
  • Thromboembolism / prevention & control*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Methotrexate